Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer
Takashi Kojima(National Cancer Center Hospital East), Toshihiko Doi(National Cancer Center Hospital East), Sung‐Bae Kim(Ulsan College), Antoine Adenis(Inserm), Jaafar Bennouna(Hôpital Foch), Raed Moh’d Taiseer Al-Rajabi(The University of Kansas Cancer Center), Shukui Qin(81th Hospital of PLA), Hélène Senellart(Institut Génétique Nantes Atlantique), Florian Lordick(Leipzig University), Éric François(Centre Antoine Lacassagne), Christelle de la Fouchardière(Aix-Marseille Université), Gustavo Girotto(Hospital de Base), Se‐Hoon Lee(Samsung Medical Center), Kei Muro(Aichi Cancer Center), Lin Shen(Peking University), Jean‐Philippe Metges(Centre Hospitalier Régional Universitaire de Brest), Ken Kato(National Cancer Center Hospital East), Manish A. Shah(NewYork–Presbyterian Hospital), Chih‐Hung Hsu(National Taiwan University of Science and Technology), Peter C. Enzinger(Dana-Farber Cancer Institute), Jia Chen(Heilongjiang University of Chinese Medicine), Ruixue Wang(Kunming University of Science and Technology), Toshikazu Moriwaki(University of Tsukuba Hospital), Soonmo Peter Kang(Merck & Co., Inc., Rahway, NJ, USA (United States)), Pooja Bhagia(Merck & Co., Inc., Rahway, NJ, USA (United States)), Shailaja Suryawanshi(Merck & Co., Inc., Rahway, NJ, USA (United States))
Cited by 1,173
Related Papers
Gastric cancer
|The Lancet|2020|4.8k
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
|Journal of Clinical Oncology|2013|3.2k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k